- Oral presentation
- Open Access
Drug resistance patterns in new and previously treated patients with tuberculosis presenting to a tertiary care center in southern India
© Udaykumar et al; licensee BioMed Central Ltd. 2014
- Published: 27 May 2014
- Drug Susceptibility Testing
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a major global health problem. It is the second leading cause of death worldwide. Drug resistance threatens global TB control with the emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB. The burden of MDR TB and XDR TB in India is not available as continuous surveillance for drug resistance is not carried out. This study was done to determine the drug resistance patterns to first and second line drugs among new and previously treated patients with TB.
Sputum samples were collected from 100 suspected TB patients from a tertiary care referral hospital. After digestion and decontamination, samples were stained for microscopy and cultured in liquid (MGIT) and Löwenstein Jensen (LJ) medium to isolate M. tuberculosis. Drug susceptibility testing (DST) was done against first line (streptomycin, isoniazid, rifampin and ethambutol) and second line (kanamycin, capreomycin, ofloxacin and ethionamide) drugs.
Among the 100 samples, 56 were smear positives and M. tuberculosis was isolated from 61 samples cultured in MGIT and 46 in L J medium. Of which 20 (32.7%) were MDR strains. Among the MDR strains, 9 (45%) were XDR strains. Two strains were totally resistant to all the 8 drugs. The proportion of MDR and XDR was highest among the previously treated patient.
This study underscores the need for DST in all TB patients particularly in the previously treated patients. New drugs, novel treatment strategies and adherence to treatment are needed to effectively treat and control drug resistant TB.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.